Corvus 制药 CRVS
$10.54 +$0.81 (+8.32%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $10.60 +0.57%
开盘$10.65
昨收$9.73
当日区间$9.64 – $10.96
成交量1.26M
市值$889.08M
市盈率（TTM）–
股息率–
CRVS 相关新闻
匹配 Corvus Pharmaceuticals 或代码 CRVS 的头条新闻，按最新排序。
- Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30
- H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27
- Corvus Pharmaceuticals (CRVS.US) will release its earnings report after market close on August 6.
- Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33
- A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40
- Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40
- Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40
- Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $33 正面
- Corvus Pharmaceuticals (CRVS.US) will release its financial report after market hours on November 5.
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Cuts Target Price to $27 负面
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $30 正面
- Jefferies Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $42 正面
- Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $28 正面
- H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $27 正面
暂无评论——快来第一个聊聊 CRVS。
登录后参与讨论。